Clinical trial · Interventional
Ginger in Treating Nausea in Patients Receiving Chemotherapy for Cancer
A Phase II/III Randomized, Controlled Clinical Trial Of Ginger (Zingiber Officinale) For Nausea Caused By Chemotherapy For Cancer
NCT00040742CI-TRIAL-00019732completedPhase 2 / Phase 3Results postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Ginger may help reduce or prevent nausea. It is not yet known if antiemetic drugs are more effective with or without ginger in treating nausea caused by chemotherapy. PURPOSE: This randomized phase II/III trial is studying giving antiemetic drugs together with ginger to see how well they work compared to antiemetic drugs alone in treating nausea in patients who are receiving chemotherapy for cancer.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Nausea | — | UNRESOLVED | — |
| Vomiting | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| ginger | Dietary Supplement | — | UNRESOLVED |
| placebo | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (4)
- type
- PLACEBO_COMPARATOR
- label
- Placebo
- description
- Patients receive oral placebo twice daily on days -3 to 3 of chemotherapy courses 2 and 3.
- interventionNames
- Other: placebo
- type
- EXPERIMENTAL
- label
- 0.5g ginger
- description
- Patients receive oral low-dose ginger and oral placebo twice daily on days -3 to 3 of chemotherapy courses 2 and 3.
- interventionNames
- Dietary Supplement: ginger
- Other: placebo
- type
- EXPERIMENTAL
- label
- 1.0g ginger
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 120 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Diagnosis of cancer and be scheduled to receive at least 3 courses of chemotherapy * Scheduled to receive chemotherapy with no planned interruption by radiotherapy or surgery * Chemotherapy courses must be separated by at least 2 weeks from day 1 to day 1 of next course * Must have experienced nausea of any degree of severity after completion of the first study-related course of chemotherapy * Received a prior 5-hydroxytryptamine type 3 (5-HT3) receptor antagonist antiemetic (ondansetron, granisetron, tropisetron, or dolasetron mesylate) with dexamethasone (DM) given at any dose and by any route (or equivalent dose of IV methylprednisolone (MePRDL)) on day 1 of course 1 of chemotherapy * Scheduled to receive a 5-HT3 receptor antagonist antiemetic with DM (or equivalent dose of IV MePRDL) on day 1 of courses 2 and 3 of chemotherapy * No symptomatic brain metastases PATIENT CHARACTERISTICS: Age: * 18 and over Performance status: * Not specified Life expectancy: * Not specified Hematopoietic: * Platelet count greater than 100,000/mm\^3 at second course of chemotherapy * No prior bleeding or blood coagulation disorder (e.g., thrombocytopenia or platelet dysfunction) Hepatic: * No prior coagulation factor deficiency Renal: * Not specified Cardiovascular: * No prior vascular defect Other: * Able to understand English * No concurrent or impending bowel obstruction PRIOR CONCURRENT THERAPY: Biologic therapy: * No concurrent interferon therapy Chemotherapy: * See Disease Characteristics * At least 6 months since other prior chemotherapy Endocrine therapy: * Not specified Radiotherapy: * See Disease Characteristics * No concurrent radiotherapy Surgery: * See Disease Characteristics Other: * No concurrent warfarin or heparin for therapeutic anticoagulation * Concurrent low-dose warfarin for maintenance of venous access allowed * Concurrent rescue medications for control of symptoms caused by the cancer or its treatment allowed as clinically indicated
References
Publications (0)
Data not yet available
No reference posted for this study.